{
    "title": "Novartis fails again to reuse anti-inflammatory drug to treat lung cancer",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11112391/Novartis-says-lung-cancer-drug-canakinumab-fails-trial.html",
    "date": "2022-08-15",
    "keywords": [
        "cancer",
        "drug",
        "lung",
        "trial",
        "novartis",
        "year",
        "john",
        "revill",
        "burger",
        "growth",
        "nonsmall",
        "cell",
        "canakinumab",
        "disease",
        "indication",
        "blow",
        "drugmaker",
        "monday",
        "progression",
        "latestage",
        "relapse",
        "tumourremoval",
        "surgery",
        "failure",
        "canopy",
        "setback",
        "combination",
        "stage",
        "consensus",
        "highrisk",
        "project",
        "market",
        "exclusivity",
        "analyst",
        "laurent",
        "flamme",
        "treatment",
        "number",
        "brand",
        "name",
        "ilaris",
        "credit",
        "suisse",
        "role",
        "type",
        "inflammation",
        "programme",
        "pharma",
        "development",
        "review",
        "business",
        "sale",
        "disposal",
        "research",
        "pipeline",
        "stake",
        "roche",
        "rival",
        "reporting",
        "frankfurt",
        "editing",
        "sitholematarise",
        "bernadette",
        "baum"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}